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1 INTRODUCTION 
Angiogenesis is a normal and vital process in growth 
and development, as well as in wound healing and in 
the formation of granulation tissue. However, it is 
also a fundamental step in the transition of tumors 
from a benign state to a malignant one, leading to 
the use of angiogenesis inhibitors in the treatment of 
cancer. 
An angiogenesis inhibitor is a substance that in-
hibits the growth of new blood vessels (angiogene-
sis). Some angiogenesis inhibitors are endogenous 
and a normal part of the body's control and others 
are obtained exogenously through pharmaceutical 
drugs or diet. 
Angiogenesis inhibitors were once thought to 
have potential as a "silver bullet" treatment applica-
ble to many types of cancer, but the limitations of 
anti-angiogenic therapy have been shown in prac-
tice. Therefore, a novel effective angiogenesis inhib-
itor is urgently needed. 
VEGF (Vascular endothelial growth factor) sig-
naling is critical for blood vessel formation and is 
involved in all stages of angiogenesis, its inhibition 
is an attractive therapy target in a wide range of tu-
mor types, and disruption of the VEGF signal has 
become one of the dominant strategies for the angi-
ogenesis-related treatment of cancer 
(Avendano,2015). 
Inhibiting angiogenesis requires treatment with 
anti-angiogenic factors or drugs which prevent pro-
angiogenic factors to bind with their receptors or to 
block their actions. All members of the VEGF fami-
ly stimulate cellular responses by being bound to the 
tyrosine kinase receptors (the VEGFRs) on the cell 
surface, causing them to dimerize and activating 
them through transphosphorylation. Inhibition of the 
VEGF pathway has become the focus of angiogene-
sis research as approximately 60% of malignant tu-
mors express high concentrations of VEGF. Strate-
gies to inhibit the VEGF pathway directed against 
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VEGF or VEGFR. VEGFR-2, a type II 
transmembrane TK receptor, expressed on endothe-
lial cells and on circulating bone marrow-derived 
endothelial progenitor cells, is the principal mediator 
of the VEGF-induced angiogenic signaling. 
VEGFR-2 is also a novel target. Biological and pre-
clinical evidence suggests that the blockage of 
VEGFR-2 could be a promising strategy to inhibit 
tumor-induced angiogenesis (Fontanella C et 
al.,2014). 
One of proved VEGFR-2 inhibitor on the market 
today is Sorafenib tosylate (Fig.1). In vitro study, 
sorafenib tosylate inhibits both wild-type and V599E 
mutant B-Raf activity with IC50 of 22 nM and 38 
nM, respectively. Sorafenib tosylate also potently 
inhibits mVEGFR-2 (Flk-1), mVEGFR-3, 
mPDGFRβ, Flt3, and c-Kit with IC50 of 15 nM, 20 
nM, 57 nM, 58 nM, and 68 nM, respectively(Lu et 
al., 2013) 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Sorafenib tosylate 
 
Suhud et al. (2015) has proven that a lead com-
pound 1-benzoyl-3-benzylurea (Fig.2) in- silico in-
hibits Raf-kinase (PDB code 1-UWH) with Rerank 
Score -90,5615 Kcal/mol and in-vitro against MCF-
7 cell line with IC50 384,87 µM. 
 
 
 
Figure 2. 1-Benzoyl-3-benzylurea 
 
Both of sorafenib and 1- benzoyl-3-benzylurea 
have the same urea functional group. In order to find 
a novel effective angiogenesis inhibitor, the recent 
study on structural modification 1-benzoyl-3-
benzylurea was conducted. All compounds will in-
terfere with the binding of VEGF to VEGFR-2, in-
hibiting VEGF-induced signal, and block cancer 
growth.  Prediction of activity as VEGFR-2 inhibitor 
would be performed by MVD 5.0 molecular dock-
ing. Prediction of bioavailability and toxicity will be 
performed by ACD-I/ Lab. 
2 METHODS  
Structural modification was carried out by substitut-
ing 22 substituents with certain physicochemical 
properties (lipophilic, electronic, and steric) into 
benzoyl group of the lead compound 1-benzoyl-3-
benzylurea: 
2-chloro; 3-chloro; 4-chloro; 2,4-dichloro; 3,4-
dichloro; 4-chlorometil; 3-chloromethyl; 2-
chloromethyl; 4-methyl; 4-ethyl; 3-ethyl; 2-ethyl; 4-
prophyl; 4-t-buthyl; 4-fluoro; 2-trifluoromethyl; 3-
trifluoromethyl; 4-trifluoromethyl; 4-bromo; 4-
bromomethyl; 4-nitro; 4-methoxy. 
2.1 Molecular docking  
Computational method in term of in-silico activity 
test is started with searching Protein Data Bank 
/PDB database (Yanuar, 2012). Molecular docking 
was done to 1-benzoyl-3-benzylurea lead and its an-
alogue compounds, also the reference hydroxyurea 
and 5-fluorouracil by Molegro Virtual Dock-
er(MVD) 2011.5. Two dimention (2D) and 3D struc-
tures were performed by ChemBioDraw Ultra 12.0 
2010 from CambridgeSoft®. 
2.2 Test parameter 
Prediction of some physicochemical properties, bio-
availability and toxicity were performed by ACD/I-
Lab Prediction Engine from Advances Chemistry 
Development, Inc. free access on 
https://ilab.acdlabs.com/iLab2/. Prediction of activi-
ty is performed by Molegro Virtual Docker 2011.5. 
Quantitative Structure- Bioavailability/ Activity/ 
Toxicity were analyzed using IBM® SPSS® versi 
20 from IBM Corp. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. Research Procedure 
 
3 RESULTS AND DISCUSSION  
Computational (in silico) methods has been done to 
bioavailability, activity and toxicity test. These in 
silico methods include databases, quantitative struc-
ture- bioavailability/ activity and toxicity relation-
ships using computer and software as tools. Such 
methods are frequently used in the discovery and op-
timization of novel compounds with affinity to a tar-
get. The aim of these in silico methods for pharma-
cology in terms of the targets addressed (Ekins S et 
al.,2007)).  
VEGFR-2 appears to mediate almost all of the 
known cellular responses to VEGF 
(https://www.ncbi.nlm.nih.gov/pmc/articles/PMC42
60048/ downloaded on 04/16/2017)  
VEGFR2 is considered to be one of the most im-
portant regulators of angiogenesis, and is a key tar-
get in anti-cancer treatment (Avendano, 2015; Endo 
et al., 2003; http://jcp.bmj.com downloaded on 
09/12/2016,). 
Inhibition of VEGFR-2 thus blocked all VEGF-
induced endothelial cellular responses tested, and 
became a potentially targeted therapy as 
antiangiogenesis (Cervello, et al., 2012; Endo et 
al.,2003) 
VEGFR-2 with PDB code (Protein Data Bank) 
4ASD was chosen because of sorafenib as a ligand. 
Sorafenib (Nexavar), approved by Food and Drug 
Administration (FDA) for the treatment of advanced 
renal cell carcinoma (RCC) in 2005 and 
unresectable hepatocellular cell carcinoma (HCC) in 
2007, is the first orally bioavailable, multi-receptor 
tyrosine  kinase  inhibitor.  This diaryl urea small 
molecule inhibits several kinases involved in tumor 
proliferation and tumor angiogenesis including Raf, 
vascular endothelial growth factor receptor 
(VEGFR), and platelet derived growth factor recep-
tor (PDGFR), (Lu et al., 2013; Avendano, 2015).  
Sorafenib is also used as a reference beside of 
hydroxyurea and 5-fluorouracil which were estab-
lished as anticancer. The same urea functional group 
in these compounds becomes the reason to dock 
hydroxyurea, 5-fluorouracil, 1-benzoyl-3-benzylurea 
lead    and its analogue compounds as antianticancer 
by VEGFR-2 inhibition. The docking result is pre-
sented in Table 1. 
 
 
  
 
Table 1. Docking results of all compounds 
No. Compound Rerank Score (kcal/mol) 
1 1-benzoyl-3-benzylurea -96,9887 
2 1-(2-chlorobenzoyl) -3-benzylurea -97,0605 
3 1- (3-chlorobenzoyl) -3-benzylurea -100,64 
4 1- (4-chlorobenzoyl) -3-benzylurea -99,0598 
5 1- (2,4-dichlorobenzoyl) -3-benzylurea -98,7292 
6 1- (3,4-dichlorobenzoyl) -3-benzylurea -104,613 
7 1- (4-chloromethylbenzoyl) -3-benzylurea -102,067 
8 1- (3-chloromethylbenzoyl) -3-benzylurea -106,427 
9 1-(2-chloromethylbenzoyl) -3-benzylurea -102,834 
10 1- (4-methylbenzoyl) -3-benzylurea -100,401 
11 1- (4-ethylbenzoyl) -3-benzylurea -101,873 
12 1- (3-ethylbenzoyl) -3-benzylurea -109,53 
13 1- (2-ethylbenzoyl) -3-benzylurea -104,537 
14 1- (4-prophylbenzoyl) -3-benzylurea -105,938 
15 1- (4-t-buthylbenzoyl) -3-benzylurea -100,14 
16 1-(4-fluorobenzoyl) -3-benzylurea -98,4593 
17 1-(2-trifluoromethylbenzoyl) -3- benzylurea -93,2305 
18 1- (3-trifluoromethylbenzoyl) -3- benzylurea -111,711 
19 1- (4-trifluoromethylbenzoyl) -3- benzylurea -104,119 
20 1-(4-bromobenzoyl) -3- benzylurea -99,6173 
21 1-(4-bromomethylbenzoyl) -3- benzylurea -100,269 
22 1- (4-nitrobenzoyl)-3- benzylurea -104,774 
23 1-(4-methoxybenzoyl) -3- benzylurea -98,6492 
24 Hydroxyurea -41,5724 
25 5-Fluorouracil -60,7791 
26 Sorafenib -136,297 
 
Rerank score -111,711 kcal/mol indicates that 1- 
(3-trifluoromethylbenzoyl)-3- benzylurea is the most 
stable D-R interaction and is predicted to have the 
best activity as VEGFR 2 inhibitor. Theoretically, 
trifluoromethyl (-CF3) changes the electronic distri-
bution because of its most electronegativity. Elec-
tronegativity is based on an arbitrary scale, with flu-
orine being the most electronegative (EN4.0). 
Fluorine attracts electrons strongly. Group with elec-
tronic effect induced D-R interaction and reduced 
electronic density (Thomas, 2003; Mc.Murry, 2011). 
Hydroxyurea and 5-fluorouracil showed rerank 
score -41,5724 Kcal/mol and -60,7791 kcal/mol that 
mean less stable D-R interaction compared to all 
tested compounds. Lipophilic groups like benzyl and 
benzoyl could stabilize D-R interaction leading to 
increasing activity. Moreover, other substituents 
with variety in lipophilic, electronic, and steric 
properties into benzoyl group seem to increase activ-
ity.  Unfortunately, all tested compounds have high-
er rerank score (in range -93,2305 to -111,711 
Kcal/mol) compared to sorafenib (-136,297 
Kcal/mol). It was probably influenced by the differ-
ence of aminoacids site bonding to sorafenib and all 
tested compounds. Sorafenib bound Asp 1046 on 
one site of –CO group and also bound Glu 885 on 
two sites of –NH from urea pharmacophore. On the 
other hand, almost all of the tested compounds 
bound Asp 1046 on one site of –CO group and only 
bound Glu 885 on one site of –NH from urea 
pharmacophore. Based on these results, all tested 
compounds have higher VEGFR-2 inhibitor activity 
compared to hydroxyurea and 5-fluorouracil but 
lower than sorafenib.  That is necessary to develop 
activity with equations below: 
- Non linear relationships between  modification of 
physicochemical properties and bioavailability 
prediction  
F>70% oral = -1.548 ClogP + 0.198 ClogP2 + 
0.125 pKa – 0.168 CMR + 3.502)  
(n = 23; r = 0,717; SE = 0,093351; F = 4,757; sig 
= 0,009) 
There is a nonlinear significant relationship be-
tween physicochemical properties and bioavail-
ability. ClogP dominantly influenced bioavail-
ability. Increasing ClogP will be followed by 
increasing in bioavailability until a certain point. 
After that, the bioavailability will decrease if 
ClogP is increased.  
- Nonlinear relationships between modification of 
physicochemical properties and activity predic-
tion  
Rerank Score = 1.802 Es + 5.421 ClogP2 – 
44.744 ClogP – 11.152 
(n = 23; r = 0,622; SE = 3,5801997; F = 4,004; 
sig = 0,023) 
There is also a non linear significant relationship 
between physicochemical properties and activity. 
ClogP take the main role in activity compared to Es.  
Increasing ClogP will be followed by increasing 
in activity until a certain point. After that, the ac-
tivity will decrease if ClogP is increased. 
- A linear relationship between modification of 
physicochemical properties and toxicity 
prediction  
LD-50 Mouse = -7.422 Mw – 117.197 pKa + 
260.565 π + 4342.379  (n = 23; r = 0,793; SE = 
140,87733; F = 10,062; sig = 0,000) There is a 
linear significant relationship between physico-
chemical properties and toxicity. π take the main 
role in reducing toxicity in mouse.  Increasing π 
will befollowed by increasing LD-50 Mouse.  
Thus mean the toxicity will decrease.  
LD-50 Rat = 691.028 CMR – 21.453 Etot – 
430.187 π – 4775.208). (n = 23; r = 0,733; SE = 
288,67963; F = 7,353; sig = 0,002) 
There is also a linear significant relationship be-
tween physicochemical properties and toxicity in 
rat.  CMR take the main role in reducing toxicity 
in rat.  Increasing CMR will be followed by in-
creasing LD-50 Rat. Thus mean the toxicity will 
decrease. 
 
These quantitative equations can be used as foun-
dations for further structural modification to discov-
er a novel potential anticancer drug with better bioa-
vailability, activity, and minimum toxicity. 
4 CONCLUSION 
There are nonlinear relationships between modifica-
tion of physicochemical properties with bioavailabil-
ity prediction (F>70% oral = -1.548 ClogP + 0.198 
ClogP2 + 0.125 pKa – 0.168 CMR + 3.502) and 
modification of physicochemical properties with ac-
tivity prediction (Rerank Score = 1.802 Es + 5.421 
ClogP2 – 44.744 ClogP – 11.152). Also, there is a 
linear relationship between modification of physico-
chemical properties and toxicity prediction (LD-50 
Mouse = -7.422 Mw – 117.197 pKa + 260.565 π + 
4342.379 and LD-50 Rat = 691.028 CMR – 21.453 
Etot – 430.187 π – 4775.208). These quantitative 
equations can be used as foundations for further 
structural modification to discover a novel potential 
anticancer drug with better bioavailability, activity, 
and minimum toxicity. 
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